Prosecution Insights
Last updated: November 20, 2026
Application No. 18/564,572

CAS13-BASED COMPOSITIONS AND METHODS OF USE THEREOF

Non-Final OA §102
Filed
Nov 27, 2023
Priority
May 27, 2020 — provisional 63/030,796 +5 more
Examiner
HASAN, KHALEDA B
Art Unit
1636
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
King Abdullah University of Science and Technology
OA Round
1 (Non-Final)
60%
Grant Probability
Moderate
1-2
OA Rounds
5m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 60% of resolved cases
60%
Career Allowance Rate
81 granted / 136 resolved
At TC average
Strong +49% interview lift
Without
With
+49.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
28 currently pending
Career history
166
Total Applications
across all art units

Statute-Specific Performance

§101
6.6%
-33.4% vs TC avg
§103
33.6%
-6.4% vs TC avg
§102
14.9%
-25.1% vs TC avg
§112
26.6%
-13.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 136 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Status Applicant’s amendment filed 8/4/2026 has been entered. Claims 5, 8, 10-14, 16, 19-23, 25-26, 28-29, 31, and 33 are cancelled. Claims 1-4, 6-7, 9, 15, 17-18, 24, 27, 30, 32, and 34-36 are pending. Claims 34-36 are new. Claims 15, 17-18, 27, 30, 32, and 35-36 are withdrawn. Claims 1-4, 6-7, 9, 24, and 34 are examined herein. Applicant amended claims 1-4, 6-7, and 9 from a composition to a method depending from claim 24 and further added new claim 34. Election/Restrictions Claims 15, 17-18, 27, 30, 32, and 35-36 withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 8/4/2026. Applicant's election with traverse of Group II, claims 1-4, 6-7, 9, 15, 17-18, 24, 27, 30, 32, and 34-36 in the reply filed on 8/4/2026 is acknowledged. The traversal is on the ground(s) that Konermann and Doudna do not teach or suggest such a method as set forth in claim 24 as amended, much less in the context of the elected species including the amino acid sequence of SEQ ID NO: 64. This is not found persuasive because the limitation requiring a specific sequence is optional in claim 24, thus not requiring SEQ ID NO: 64. The requirement is still deemed proper and is therefore made FINAL. Applicant’s election without traverse of a. in the reply filed on 8/4/2026 is acknowledged. Note: SEQ ID NO: 193 is recited in withdrawn claim 17 and will therefore not be searched. Nucleotide and/or Amino Acid Sequence Disclosures Summary of Requirements for Patent Applications Filed On Or After July 1, 2022, That Have Sequence Disclosures 37 CFR 1.831(a) requires that patent applications which contain disclosures of nucleotide and/or amino acid sequences that fall within the definitions of 37 CFR 1.831(b) must contain a “Sequence Listing XML”, as a separate part of the disclosure, which presents the nucleotide and/or amino acid sequences and associated information using the symbols and format in accordance with the requirements of 37 CFR 1.831-1.835. This “Sequence Listing XML” part of the disclosure may be submitted: 1. In accordance with 37 CFR 1.831(a) using the symbols and format requirements of 37 CFR 1.832 through 1.834 via the USPTO patent electronic filing system (see Section I.1 of the Legal Framework for Patent Electronic System (https://www.uspto.gov/PatentLegalFramework), hereinafter “Legal Framework”) in XML format, together with an incorporation by reference statement of the material in the XML file in a separate paragraph of the specification (an incorporation by reference paragraph) as required by 37 CFR 1.835(a)(2) or 1.835(b)(2) identifying: a. the name of the XML file b. the date of creation; and c. the size of the XML file in bytes; or 2. In accordance with 37 CFR 1.831(a) using the symbols and format requirements of 37 CFR 1.832 through 1.834 on read-only optical disc(s) as permitted by 37 CFR 1.52(e)(1)(ii), labeled according to 37 CFR 1.52(e)(5), with an incorporation by reference statement of the material in the XML format according to 37 CFR 1.52(e)(8) and 37 CFR 1.835(a)(2) or 1.835(b)(2) in a separate paragraph of the specification identifying: a. the name of the XML file; b. the date of creation; and c. the size of the XML file in bytes. SPECIFIC DEFICIENCIES AND THE REQUIRED RESPONSE TO THIS NOTICE ARE AS FOLLOWS: Specific deficiency - Sequences appearing in the drawings at Figures 10G, 10K, 10M, 14A-14D, and 14F-14I are not identified by sequence identifiers in accordance with 37 CFR 1.831(c). Sequence identifiers for sequences (i.e., “SEQ ID NO:X” or the like) must appear either in the drawings or in the Brief Description of the Drawings. Required response – Applicant must provide: Amended drawings in accordance with 37 CFR 1.121(d) inserting the required sequence identifiers; AND/OR A substitute specification in compliance with 37 CFR 1.52, 1.121(b)(3), and 1.125 inserting the required sequence identifiers (i.e., “SEQ ID NO:X” or the like) into the Brief Description of the Drawings, consisting of: • A copy of the previously-submitted specification, with deletions shown with strikethrough or brackets and insertions shown with underlining (marked-up version); • A copy of the amended specification without markings (clean version); and • A statement that the substitute specification contains no new matter. Specification The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code at pages 139, 140, and 183. Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code; references to websites should be limited to the top-level domain name without any prefix such as http:// or other browser-executable code. See MPEP § 608.01. Drawings The drawings are objected to because FIGs. 10K, 10M, 11A, 14A-14D, 14F-14I, 15A, 15B, and 17A are illegible and pixelated. Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1-4, 6-7, 9, 24, and 34 are rejected under 35 U.S.C. 102(a)(2) as being anticipated by Zhang et al. (US20230025039A1; published 1/23/2023, with priority to 62/903,604, filed Sep. 20, 2019). Regarding independent claim 24, Zhang teaches methods of modifying target RNA sequences to knockdown expression of RNA transcript by delivering to a cell polynucleotides comprising sequence encoding Cas13a and crRNA, where the heterologous Cas13 and crRNA form a complex and cleave the RNA target sequence (claims 1, 5, 15-16, 18, 52, and 69-75; paras 0089-0090; 0495-0496, 0236-0239; 0617-0618). Zhang teaches SEQ ID NO: 60 encoding Cas13a having 99.8% sequence to Applicant’s elected SEQ ID NO: 64, which is greater than the required at least 70% sequence identity (claim 5; see below). (Qy: Applicant’s elected SEQ ID NO: 64) Qy 1 MKITKRKWGEHHPPLYFYRDEDSGRLLAQNDRKQDYTDTLFNDIAQDTFERSLRNRLLKT 60 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 1 MKITKRKWGEHHPPLYFYRDEDSGRLLAQNDRKQDYTDTLFNDIAQDTFERSLRNRLLKT 60 Qy 61 PEKGDKRFYSNEIVKLVEKLCQGADVAEIMKSMERNEKLRPKNEKEIKNLKKQLDGTLSE 120 |||||||||||||||||||||||||||||||||||:|||||||||||||||||||||||| Db 61 PEKGDKRFYSNEIVKLVEKLCQGADVAEIMKSMERSEKLRPKNEKEIKNLKKQLDGTLSE 120 Qy 121 YGKRYTAPEGAMTLNDALFYLVEGNPLKQAMAKAELGKIREALIKEKENRINRVRYSIKN 180 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 121 YGKRYTAPEGAMTLNDALFYLVEGNPLKQAMAKAELGKIREALIKEKENRINRVRYSIKN 180 Qy 181 NKIPLRIQEDGGITPNNDRAAWLLGLMKPADPAKGITDCYPLLGELEEVFDFDKLSKTLH 240 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 181 NKIPLRIQEDGGITPNNDRAAWLLGLMKPADPAKGITDCYPLLGELEEVFDFDKLSKTLH 240 Qy 241 EKISRCQGRPRSIAMAVDEALKQYLRELWEKSPSRQQDLKYYFQAVQEYFKDNFPIRTKR 300 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 241 EKISRCQGRPRSIAMAVDEALKQYLRELWEKSPSRQQDLKYYFQAVQEYFKDNFPIRTKR 300 Qy 301 MGARLRQELLKDKTSLSRLLEPKHMANAVRRRLINQSTQMHILYGKLYAYCCGEDGRLLV 360 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 301 MGARLRQELLKDKTSLSRLLEPKHMANAVRRRLINQSTQMHILYGKLYAYCCGEDGRLLV 360 Qy 361 NSETLQRIQVHEAVKKQAMTAVLWSISRLRYFYQFEDGDILSNKNPIKDFRDKFLRDTNK 420 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 361 NSETLQRIQVHEAVKKQAMTAVLWSISRLRYFYQFEDGDILSNKNPIKDFRDKFLRDTNK 420 Qy 421 YTHEDVEACKEKLQDFFPLKELQEKIKEDAKGLQETDNKQADTTDFKAIGHIVRDDRKLC 480 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 421 YTHEDVEACKEKLQDFFPLKELQEKIKEDAKGLQETDNKQADTTDFKAIGHIVRDDRKLC 480 Qy 481 NQLLAECVSCIGELRHHIFHYKNVTLIQALKRIADKVKPEDLSVLRAIYLLDRRNLKKAF 540 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 481 NQLLAECVSCIGELRHHIFHYKNVTLIQALKRIADKVKPEDLSVLRAIYLLDRRNLKKAF 540 Qy 541 AKRISSMNLPLYYREDLLSRIFKKEGTAFFLYSAKIQMTPSFQRVYERGKNLRREFECER 600 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 541 AKRISSMNLPLYYREDLLSRIFKKEGTAFFLYSAKIQMTPSFQRVYERGKNLRREFECER 600 Qy 601 MKAEASNGQNGQDGDRLKWFRQLAAGDSADTHFNWAVEAYAESAADVENNVEFDTDVDAQ 660 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 601 MKAEASNGQNGQDGDRLKWFRQLAAGDSADTHFNWAVEAYAESAADVENNVEFDTDVDAQ 660 Qy 661 RALRNLLLLIYRHHFLPEVQKDETLVTGKIHKVLERNRQLSEGQGPNQGKAHGYSVIEEL 720 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 661 RALRNLLLLIYRHHFLPEVQKDETLVTGKIHKVLERNRQLSEGQGPNQGKAHGYSVIEEL 720 Qy 721 YHEGMPLSDLMKQLQRRISETERESRELAQEKTDYAQRFILDIFAEAFNDFLEAHYGEEY 780 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 721 YHEGMPLSDLMKQLQRRISETERESRELAQEKTDYAQRFILDIFAEAFNDFLEAHYGEEY 780 Qy 781 LEIMSPRKDAEAAKKWVKESKTVDLKTSIDEKEPEGHLLVLYPVLRLLDERELGELQQQM 840 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 781 LEIMSPRKDAEAAKKWVKESKTVDLKTSIDEKEPEGHLLVLYPVLRLLDERELGELQQQM 840 Qy 841 IRYRTSLASWQGESNFSEEIRIAGQIEELTELVKLTEPEPQFAEEVWGKRAKEAFEDFIE 900 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 841 IRYRTSLASWQGESNFSEEIRIAGQIEELTELVKLTEPEPQFAEEVWGKRAKEAFEDFIE 900 Qy 901 GNMKNYEAFYLQSDNNTPVYRRNMSRLLRSGLMGVYQKVLASHKQALKRDYLLWSEKHWN 960 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 901 GNMKNYEAFYLQSDNNTPVYRRNMSRLLRSGLMGVYQKVLASHKQALKRDYLLWSEKHWN 960 Qy 961 VKDENGADISSAEQAQCLLQRLHRKYAESPSRFTEEDCKLYEKVLRRLEDYNQAVKNLSF 1020 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 961 VKDENGADISSAEQAQCLLQRLHRKYAESPSRFTEEDCKLYEKVLRRLEDYNQAVKNLSF 1020 Qy 1021 SSLYEICVLNLEILSRWVGFVQDWERDMYFLLLAWVRQGKLDGIKEEDVRDIFSEGNIIR 1080 |||||||||||||||||||||||||||||||||||||||||||||||:|||||||||||| Db 1021 SSLYEICVLNLEILSRWVGFVQDWERDMYFLLLAWVRQGKLDGIKEENVRDIFSEGNIIR 1080 Qy 1081 NLVDTLKGENMNAFESVYFPENKGSKYLGVRNDVAHLDLMRKNGWRLEAGKTCSVMEDYI 1140 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 1081 NLVDTLKGENMNAFESVYFPENKGSKYLGVRNDVAHLDLMRKNGWRLEAGKTCSVMEDYI 1140 Qy 1141 NRLRFLLSYDQKRMNAVTKTLQQIFDRHKVKIRFTVEKGGMLKIEDVTADKIVHLKGSRL 1200 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 1141 NRLRFLLSYDQKRMNAVTKTLQQIFDRHKVKIRFTVEKGGMLKIEDVTADKIVHLKGSRL 1200 Qy 1201 SGIEIPSHGERFIDTLKALMVYPRG 1225 ||||||||||||||||||||||||| Db 1201 SGIEIPSHGERFIDTLKALMVYPRG 1225 (Db: Zhang’s SEQ ID NO: 60) Regarding claim 1, Zhang teaches polynucleotides encoding the Cas protein (claim 1, 5, 52, 59). As detailed above regarding claim 24, Zhang teaches the SEQ ID NO: 60 with 99.8% identity to Applicant’s elected SEQ ID NO: 64. Therefore, the polynucleotide sequence encoding a Cas13 sequence with 1223/1225 matches would inherently have a polynucleotide sequence with at least 70% sequence identity. Regarding claim 2, Zhang teaches that the nucleotide sequence encoding the Cas effector protein is codon optimized for expression in a eukaryotic cell (claims 1, 5, and 53-54; paras 0168-0170, 0525-0527 and 0773). Regarding claims 3 and 4, Zhang teaches the Cas effector protein further comprising heterologous sequences, such as one or more protease recognition sites (claims 1, 5, 14, and 15; paras 0196, 0411). Zhang further teaches vector systems comprising regulatory elements operably linked to a nucleotide sequence encoding the Cas protein (claims 1, 5, and 53). Zhang teaches vectors and expression cassettes comprising regulatory elements comprising a promoter, terminator, multiple-cloning site, drug resistance marker, or epitope tags (paras 0183-0186, 0207, 0246, 0264, 0573-0579, 0786, 1275-1278). Regarding claim 6, Zhang teaches the Cas effector protein derived from a Proteobacteria bacterium (Lachnospiraceae bacterium) (paras 0234-0236). Regarding claim 7, Zhang teaches further teaches polynucleotide vector systems comprising a nucleotide sequence encoding the Cas protein (claims 1, 5, and 53; paras 0183-0186, 0207, 0246, 0264, 0573-0579, 0786, 1275-1278). The sequences recited in claim 7 are optional and are therefore not required. Regarding claim 9, Zhang teaches that the cell can be a eukaryotic cell (claims 1, 5, and 53-54; paras 0098-0101, 0168-0170, 0177-0179, 0184, 0254-0255, 0525-0527, and 0773). Regarding claim 34, Zhang teaches the thermostable Cas13 orthologs that form a complex with crRNA complex binding to RNA transcript at higher temperatures including the range of 50°C to 70°C, inclusive (paras 0244-0245). Allowable Subject Matter SEQ ID NO: 69 appears to be free of the prior art. SEQ ID NO: 69 is a 9761 bp polynucleotide sequence encoding an expression vector encoding TccCas13a (instant specification pages 41-47). The closest prior art in Aldor et al. (US20130122562A1; published 5/16/2013) discloses a 6693 bp polynucleotide comprising 43.1% match to SEQ ID NO: 69 (see OA.Appendix for Sequence Alignment). Conclusion No claim is allowed. Prior Art Not Relied Upon Blake et al. (US20230183783A1; published 6/15/2023 with priority to 62/966,527; filed Jan. 27, 2020) discloses SEQ ID NO: 1 encoding a 1225 aa TccCas13a with 100% sequence identity to Applicant’s claimed SEQ ID NO: 64 (see OA.Appendix for Sequence Alignment). Blake further teaches crRNA sequences for the TccCas13a to (Example 3). However, Blake does not teach using the Cas13a for targeted knockdown of RNA transcript in a cell. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KHALEDA B HASAN whose telephone number is (571)272-0239. The examiner can normally be reached IFP, Monday - Friday 7:30am-5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Neil Hammell can be reached at (571) 270-5919. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /KHALEDA B HASAN/Examiner, Art Unit 1636 /NEIL P HAMMELL/Supervisory Patent Examiner, Art Unit 1636
Read full office action

Prosecution Timeline

Nov 27, 2023
Application Filed
Oct 21, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12774347
ISOLATED IMMUNE CELL EXPRESSING A RECEPTOR, INTERLEUKIN-7, AND CHEMOKINE (C-C MOTIF) LIGAND 19
1y 6m to grant Granted Oct 27, 2026
Patent 12758573
RNA ACTION INHIBITOR AND USE THEREOF
4y 7m to grant Granted Oct 13, 2026
Patent 12747441
RIBOSWITCH MODULATED GENE THERAPY FOR RETINAL DISEASES
3y 2m to grant Granted Sep 29, 2026
Patent 12742172
ENGINEERED DNA MOLECULE FOR CODING RNA
1y 6m to grant Granted Sep 22, 2026
Patent 12697400
GENE EDITING METHODS FOR TREATING ALPHA-1 ANTITRYPSIN (AAT) DEFICIENCY
2y 3m to grant Granted Aug 04, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
60%
Grant Probability
99%
With Interview (+49.3%)
3y 5m (~5m remaining)
Median Time to Grant
Low
PTA Risk
Based on 136 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month